Review
Immunology
Espen Basmo Ellingsen, Sara M. Mangsbo, Eivind Hovig, Gustav Gaudernack
Summary: Telomerase-based therapeutic cancer vaccines have shown potential in clinical research and may enhance the efficacy of checkpoint inhibition. With its almost universal presence in cancer and essential role in tumor growth, telomerase is an attractive therapeutic target. Rational treatment combinations, such as checkpoint inhibitors, are likely necessary to fully unlock the clinical potential of telomerase-based cancer vaccines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Engineering, Environmental
Gaizhen Kuang, Qingfei Zhang, Yunru Yu, Xiaoya Ding, Weijian Sun, Xian Shen, Yuanjin Zhao
Summary: Immunotherapy is important for treating malignant tumors. A sponge-nanofiber Janus scaffold has been developed for tumor postoperative immuno-chemotherapy, containing lyophilization-inactivated cancer cells, immune adjuvant imiquimod, and 5-fluorouracil (5-FU). The scaffold exhibits excellent anti-recurrence and anti-metastasis efficiency in a mouse breast tumor model, making it a promising option for combination therapy after tumor surgery.
CHEMICAL ENGINEERING JOURNAL
(2023)
Review
Oncology
M. James Lonie, P. Andrew Barbour, Riccardo Dolcetti
Summary: OAC incidence is rising globally, but current treatment regimens have limited success, highlighting the need for improved immunotherapeutic strategies. Understanding the immune responses to OAC is essential for enhancing therapeutic approaches and potentially improving patient outcomes.
CANCER TREATMENT REVIEWS
(2021)
Review
Oncology
Jian Liu, Minyang Fu, Manni Wang, Dandan Wan, Yuquan Wei, Xiawei Wei
Summary: Research on tumor immunotherapy has made significant progress, and cancer vaccines have emerged as a promising therapeutic strategy. Cancer vaccines stimulate anti-tumor immunity with tumor antigens, potentially overcoming immune suppression and inducing both humoral and cellular immunity. This review introduces the working mechanism of cancer vaccines, summarizes different development platforms, and highlights their clinical research progress, with a focus on clinical application and therapeutic efficacy.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylosmaki, Sari Pesonen, Rui M. M. Branca, Janne Lehtio, Vincenzo Cerullo
Summary: This study explores a novel oncolytic adenovirus vaccine platform as immunotherapy in resistant tumors, customized for improved tumor targeting based on experimentally discovered tumor antigens; the pipeline may be applied for designing personalized therapeutic cancer vaccines, which is crucial for broader design and utility of therapeutic cancer vaccines. The study integrates immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy, showing promising control of established tumors using a flexible and specific tumor targeting oncolytic adenovirus platform.
Review
Chemistry, Multidisciplinary
Yunfei Yi, Mian Yu, Wen Li, Dunwan Zhu, Lin Mei, Meitong Ou
Summary: The development of therapeutic cancer vaccines using nanotechnology has great potential in improving the limitations of current immunotherapies. Nanoparticles enhance vaccine stability and antigen recognition through their small size, while surface modifications allow targeted delivery. Nanocarriers with adjuvant effect also improve vaccine efficacy. Additionally, nanoparticle-mediated chemotherapy and radiotherapy induce the release of tumor antigens, simulating anti-tumor immune responses. These vaccine-like nanomedicines can effectively eliminate tumors and prevent recurrence and metastasis. This article presents recent advancements in nanoparticle-based antigen delivery for in situ anti-tumor vaccination and discusses the remaining opportunities and challenges for clinical translation.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Chemistry, Multidisciplinary
Wen-Hao Li, Jing-Yun Su, Yan-Mei Li
Summary: Cancer vaccines aim to enhance tumor-specific immune responses by engaging both T-cell and B-cell immunity. Different factors, including antigen selection, immune activation, vaccine delivery, and repeatable vaccination, should be considered for the rational design of therapeutic cancer vaccines. Chemical strategies such as adjuvants and nanomaterials play crucial roles in advancing the development of effective T-cell- and B-cell-based cancer vaccines.
ACCOUNTS OF CHEMICAL RESEARCH
(2022)
Article
Engineering, Biomedical
Qiu-Ling Zhang, Sheng Hong, Xue Dong, Di-Wei Zheng, Jun-Long Liang, Xue-Feng Bai, Xia-Nan Wang, Zi-Yi Han, Xian-Zheng Zhang
Summary: This study presents a strategy for simplifying antigen presentation by extracellular degradation of antigen proteins into peptides, leading to improved utilization of cancer antigens and enhanced cancer immunity. The approach demonstrates potential for personalized anti-cancer therapy and has implications for expanding immunology fields and translational medicine.
Review
Materials Science, Biomaterials
Nian Liu, Xiangyu Xiao, Ziqiang Zhang, Chun Mao, Mimi Wan, Jian Shen
Summary: Cancer vaccines are a promising therapeutic strategy in clinical oncology, stimulating antitumor immunity to fight against cancer. However, there are several challenges that hinder their broad clinical translation.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2023)
Review
Chemistry, Medicinal
Dong-Hee Lee, Seunghyun Choi, Yoon Park, Hyung-seung Jin
Summary: The MUC family is highly glycosylated macromolecules abundantly expressed in mammalian epithelial cells, contributing to the mucus barrier formation against infection. Some MUC proteins are aberrantly expressed in cancer cells, involved in cancer development and progression, regarded as promising therapeutic targets and biomarkers.
Review
Immunology
Madhu Gupta, Abhishek Wahi, Priyanka Sharma, Riya Nagpal, Neha Raina, Monika Kaurav, Jaydeep Bhattacharya, Sonia M. Rodrigues Oliveira, Karma G. Dolma, Alok K. Paul, Maria de Lourdes Pereira, Polrat Wilairatana, Mohammed Rahmatullah, Veeranoot Nissapatorn
Summary: Cancer is a chronic disease with limited treatment options. Therapeutic cancer vaccines enhance the effectiveness of anticancer drugs and deliver them to the target site. These vaccines induce long-term antitumor memory and prevent tumor recurrence or metastasis.
Review
Oncology
Francesco Chierigo, Mike Wenzel, Christoph Wuernschimmel, Rocco Simone Flammia, Benedikt Horlemann, Zhe Tian, Fred Saad, Felix K. H. Chun, Derya Tilki, Shahrokh F. Shariat, Michele Gallucci, Marco Borghesi, Nazareno Suardi, Carlo Terrone, Pierre Karakiewicz
Summary: In first-line treatment for metastatic UC, IO regimens do not provide a survival benefit compared to CT, but exclusive IO regimens have lower rates of adverse events. In second-line treatment, only pembrolizumab shows a survival benefit compared to CT, while atezolizumab only demonstrates a survival benefit in exploratory analyses.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Review
Medicine, Research & Experimental
Gustav van Niekerk, Angus G. Dalgleish, Fourie Joubert, Annie Joubert, Anna-Mart Engelbrecht
Summary: Insulin regulates immune cell phenotypes through the PI3K/Akt/mTOR pathway, potentially impacting ICB therapy; Insulin interacts with immune pathways such as JAK/STAT, and is regulated by PD-1 and CTLA-4.
Review
Oncology
Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina-Cerrillo, Enrique Grande, Nicola Battelli, Francesco Massari
Summary: In the MOUSEION-03 study, a meta-analysis was conducted to determine the possibility of achieving complete remissions (CR) with immunotherapy or immuno-oncology combinations in cancer patients. The results showed that the use of immunotherapy can significantly increase the chance of achieving complete remission in cancer patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Deying Yang, Xiang Luo, Qinghai Lian, Lingqiang Gao, Chengxin Wang, Xiaoxiao Qi, Rong Zhang, Zhongqiu Liu, Guochao Liao
Summary: This study presents a new strategy for self-adjuvanting vaccine development using different types of covalently-linked immunostimulants as the carrier molecule. A three-component vaccine (MPLA-Tn-KRN7000) containing the TLR4 ligand MPLA and the iNKT cell agonist KRN7000 was designed and synthesized, expanding the field of fully synthetic self-adjuvanting vaccines. The immunological evaluation showed that MPLA-Tn-KRN7000 induced robust Tn-specific and T cell-dependent immunity.
ACTA PHARMACEUTICA SINICA B
(2022)
Meeting Abstract
Oncology
Luke Meininger, Ravi Amrit Madan, Nicole Toney, Renee Nicole Donahue, Margaret Elena Gatti-Mays, Julius Strauss, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Lisa M. Cordes, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Elias Bin Aris Chandran, Mohammad O. Atiq, Renee Nicole Donahue, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jason M. Redman, Yo-Ting Tsai, Benjamin A. Weinberg, Renee N. Donahue, Shruti Gandhy, Margaret E. Gatti-Mays, Houssein Abdul Sater, Marijo Bilusic, Lisa M. Cordes, Seth M. Steinberg, Jennifer L. Marte, Caroline Jochems, Sunnie S. Kim, John L. Marshall, Sheri McMahon, Erica Redmond, Jeffrey Schlom, James L. Gulley, Julius Strauss
Summary: This study compared the effectiveness of the standard of care with and without the addition of Avelumab and AdCEA vaccine in the treatment of metastatic colorectal cancer. The results showed that while the combination treatment generated a multifunctional immune response, it did not improve progression-free survival. Additional agents may be required to enhance the clinical benefit.
Article
Oncology
Marijo Bilusic, Nicole J. Toney, Renee N. Donahue, Susan Wroblewski, Matthew Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman
Summary: This study investigated the effects of metformin in prostate cancer treatment through a phase 2 trial. The results showed that metformin monotherapy induced modest declines in serum PSA levels in some patients and had an impact on immune cell subsets. However, the combination of metformin and bicalutamide did not improve the rate of achieving undetectable PSA at 32 weeks.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Editorial Material
Oncology
Marijo Bilusic
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Oncology
Keith T. Schmidt, Fatima Karzai, Marijo Bilusic, Lisa M. Cordes, Cindy H. Chau, Cody J. Peer, Susan Wroblewski, Alwin D. R. Huitema, Jan H. M. Schellens, James L. Gulley, William L. Dahut, William D. Figg, Ravi A. Madan
Summary: This article reports the results of a trial evaluating the efficacy of NLG207 in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide. The study found that the combination treatment was not well tolerated in patients, leading to the termination of the study.
Article
Oncology
Benjamin J. Rich, Chris Montoya, William H. Jin, Benjamin O. Spieler, Brandon A. Mahal, Rodrigo Delgadillo, Marijo Bilusic, Matthew C. Abramowitz, Alan Pollack, Alan Dal Pra
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley
Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.
Article
Oncology
Ravi A. Madan, Marijo Bilusic, Mark N. Stein, Renee N. Donahue, Philip M. Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M. Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D. Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley
Summary: This study compared the efficacy of Flutamide with or without PROSTVAC in patients with non-metastatic castration resistant prostate cancer, and the results showed that the addition of PROSTVAC did not improve patient outcomes.
Meeting Abstract
Oncology
B. J. Rich, C. Montoya, W. Jin, B. Spieler, B. A. Mahal, R. Delgadillo, M. Bilusic, M. C. Abramowitz, A. Dal Pra
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Meeting Abstract
Oncology
R. A. Madan, R. Donahue, Y-T. Tsai, F. Karzai, S. Gandhy, M. Bilusic, P. Arlen, M. Theoret, J. Marte, L. Cordes, A. Couvillon, A. Hankin, M. Williams, S. McMahon, W. D. Figg, W. Dahut, J. Schlom, J. Gulley
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Michael J. Nathenson, Junxiao Hu, Ravin Ratan, Neeta Somaiah, Robert Hsu, Peter J. DeMaria, Heath W. Catoe, Angela Pang, Ty K. Subhawong, Behrang Amini, Kevin Sweet, Katharina Feister, Karan Malik, Jyothi Jagannathan, Marta Braschi-Amirfarzan, Jamie Sheren, Yupanqui Caldas, Cristiam Moreno Tellez, Andrew E. Rosenberg, Alexander J. Lazar, Robert G. Maki, Pasquale Benedetto, Jonathan Cohen, Jonathan C. Trent, Vinod Ravi, Shreyaskumar Patel, Breelyn A. Wilky
Summary: The purpose of this study was to determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. The results showed that mutation subtype did not affect responses to specific systemic therapies. APC mutations and nonextremity desmoid tumor locations were associated with worse outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
